People · Operator
Named in public records as an officer, director or promoter · active 2016–2022 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Paradigm Diagnostics, Inc. | — | Pharmaceuticals | Series A | $11.0M | $340.1M | 2016 |
| MatriSys Bioscience, Inc. | — | Biotechnology | Series A | $8.4M | $113.7M | 2022 |
Carey Ng at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carey Ng on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Scott Morris | 1 | 8 |
| Magda Marquet | 1 | 6 |
| Rodney Markin | 1 | 4 |
| Grace Colon | 1 | 4 |
| James Mackay | 1 | 4 |
| David Neal | 1 | 2 |
| Philippe Calais | 1 | 1 |
| David Mallery | 1 | 1 |
| Erin Curley | 1 | 1 |
| Robert Armknecht | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.